Literature DB >> 28811330

Epithelial-to-Mesenchymal and Mesenchymal-to-Epithelial Transition in Mesenchymal Tumors: A Paradox in Sarcomas?

Giuseppina Sannino1, Aruna Marchetto1, Thomas Kirchner2,3,4, Thomas G P Grünewald5,2,3,4.   

Abstract

The epithelial-to-mesenchymal transition (EMT) is a reversible process comprised of various subprograms via which epithelial cells reduce their intercellular adhesions and proliferative capacity while gaining a mesenchymal phenotype with increased migratory and invasive properties. This process has been well described in several carcinomas, which are cancers of epithelial origin, and is crucial to metastatic tumor cell dissemination and drug resistance. In contrast, the precise role of EMT-related processes in tumors originating from mesenchymal tissues, such as bone and soft-tissues sarcomas, is still largely unclear. In fact, although the existence of the EMT in sarcomas appears paradoxical because these cancers are, by definition, mesenchymal ab initio, accumulating evidence suggests that many sarcomas can undergo EMT-related processes, which may be associated with aggressive clinical behavior. These processes may be especially operative in certain sarcoma subtypes, such as carcinosarcomas displaying a biphenotypic morphology with characteristics of both mesenchymal and epithelial tumors. In this review, we discuss findings regarding the potential existence of EMT-related processes in sarcomas and propose that sarcomas can reside in a metastable state, enabling them to become either more mesenchymal or epithelial under specific conditions, which likely has important clinical implications. Cancer Res; 77(17); 4556-61. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28811330     DOI: 10.1158/0008-5472.CAN-17-0032

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  A multi-layered hybrid model for cancer cell invasion.

Authors:  Sounak Sadhukhan; P K Mishra
Journal:  Med Biol Eng Comput       Date:  2022-02-28       Impact factor: 2.602

2.  Pan-sarcoma characterization of lncRNAs in the crosstalk of EMT and tumour immunity identifies distinct clinical outcomes and potential implications for immunotherapy.

Authors:  Deyao Shi; Shidai Mu; Feifei Pu; Binlong Zhong; Binwu Hu; Muradil Muhtar; Wei Tong; Zengwu Shao; Zhicai Zhang; Jianxiang Liu
Journal:  Cell Mol Life Sci       Date:  2022-07-16       Impact factor: 9.207

3.  EGFR expression in circulating tumor cells from high-grade metastatic soft tissue sarcomas.

Authors:  Alexcia Camila Braun; Celso Abdon Lopes de Mello; Marcelo Corassa; Emne Ali Abdallah; Ana Cláudia Urvanegia; Vanessa Silva Alves; Bianca C T C P Flores; Mônica Díaz; Ulisses Ribaldo Nicolau; Virgilio Souza E Silva; Vinicius Calsavara; Patrizia Paterlini-Brechót; Ludmilla Thomé Domingos Chinen
Journal:  Cancer Biol Ther       Date:  2018-03-21       Impact factor: 4.742

4.  [Silencing long non-coding RNA HIF1A-AS2 inhibits proliferation, invasion and migration of cervical cancer cells in vitro].

Authors:  Rong Deng; Fuyun Zhang; Fuzhen Lei; Wenjun Liu; Sisun Liu; Wenhua Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-11-30

5.  PB01 suppresses radio-resistance by regulating ATR signaling in human non-small-cell lung cancer cells.

Authors:  Tae Woo Kim; Da-Won Hong; Sung Hee Hong
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

Review 6.  Research models and mesenchymal/epithelial plasticity of osteosarcoma.

Authors:  Xiaobin Yu; Jason T Yustein; Jianming Xu
Journal:  Cell Biosci       Date:  2021-05-22       Impact factor: 7.133

7.  Role of Periostin Expression in Canine Osteosarcoma Biology and Clinical Outcome.

Authors:  Lauren N Alfino; Kai C Wilczewski-Shirai; Kathryn E Cronise; Jonathan Coy; Kristina Glapa; E J Ehrhart; Joseph B Charles; Dawn L Duval; Daniel P Regan
Journal:  Vet Pathol       Date:  2021-03-09       Impact factor: 3.157

Review 8.  Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice.

Authors:  Chiara Agnoletto; Chiara Caruso; Cecilia Garofalo
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639

Review 9.  Metabolic landscapes in sarcomas.

Authors:  Richard Miallot; Franck Galland; Virginie Millet; Jean-Yves Blay; Philippe Naquet
Journal:  J Hematol Oncol       Date:  2021-07-22       Impact factor: 17.388

Review 10.  Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Authors:  Victoria Damerell; Michael S Pepper; Sharon Prince
Journal:  Signal Transduct Target Ther       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.